<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1B52B94A-9456-4176-B6D1-1A4415548D28"><gtr:id>1B52B94A-9456-4176-B6D1-1A4415548D28</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:surname>Philpott</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL021129%2F1"><gtr:id>1CEE0A8C-E4BF-4129-B13A-8F58BA37C1B1</gtr:id><gtr:title>Rational strategies for neuronal production and maturation from human cells.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L021129/1</gtr:grantReference><gtr:abstractText>Recent exciting finding have shown that normal cells from the skin (fibroblasts) can be converted directly to nerve cells by the addition of only 3 or 4 new specific proteins including so-called &amp;quot;proneural factors&amp;quot;. This has opened up a wealth of possibilities for using these neurons to study nerve defects in conditions such as Parkinsons outside the body, and as a platform to test drugs that may enhance neural cell function. Moreover, findings in this area may ultimately underpin developments of methods to produce nerve cells to transplant back into patients with diverse neurological deficits.

 However, for these nerve cells to be used to model disease in a petri dish, or indeed as a supply to replace nerve cells lost in neurological disease, we need to be able to generate lots of mature nerve cells from fibroblasts that come straight from patients (as opposed to fibroblasts that have been chosen specifically for their ability to grow well in the lab). In addition, we need a way to direct the fibroblasts to form the correct type of nerve cell (e.g. cortical neurons for Stroke, dopaminergic nerve cells for Parkinsons disease, motor neurons for spinal cord injury or motor neuron disease). We are using our knowledge of the regulation of the proteins, and specifically a hyperactive protein that we think will drive much better maturation of these nerves as it does in the developing embryo, to create more effective protocols for making mature nerve cells from patient samples. We will see whether nerve cells generated in this way from patient fibroblasts look and behave the same as nerves produced from different patient-derived cells that have been produced in another way, via a stage that converts them to a &amp;quot;naive&amp;quot; form usually found in the early embryo (so called induced pluripotent cells). 

If we can use our hyperactive protein to enhance generation of mature nerves of specific types, we will then look at the genes turned on in these nerves to further explore why our neuronal differentiation factor is hyperactive.</gtr:abstractText><gtr:technicalSummary>Generation of human neurons in vitro is prerequisite for development of disease-in-a-dish models of neurodegenerative disorders, and ultimately for producing neurons for transplantation. However, for these applications to be realized, neurons generated must be mature, of defined subtype and with normal electrophysiological function. Recently, neurons have been generated from human fibroblasts and ES cells in vitro (iN cells) using defined transcription factors, with and without additional small molecules. However, the neurons generated have frequently been disappointingly immature. 
The proneural transcription factor Ascl1, used extensively in these protocols, is a crucial regulator of multiple aspects of neurogenesis, including progenitor maintenance, neuronal differentiation, and neuronal subtype. We find that using a modified form of Ascl1 that cannot be phosphorylated on Ser-Pro sites greatly increases the morphological and functional maturity of iN cells produced from human fibroblasts. Our data indicates that phosphomutant Ascl1 will also enhance generation of mature neurons from ES cells.
 We aim to manipulate phosphoregulation of Ascl1 to enhance maturation of human neurons generated in vitro, and to characterize the processes involved.
Experimentally, we will 
1) Compare expression of WT and phosphomutant forms of Ascl1 to characterize effects on differentiation, maturation and neuronal subtype after iN cell generation from human fibroblasts and hES cells, in the presence and absence of signaling modulators.
2) Compare in vitro generated neurons produced by direct fibroblast transdifferentiation and via transcription factor expression in iPS cells from the same familial alzheimers patients to compare modelling methods.
3) Use genome-wide ChIPseq and RNA seq to identify key targets that respond differentially to Ascl1 phosphostatus and to use ChIP proteomics to identify potential differences in co-factor association controlled by phospho-status.</gtr:technicalSummary><gtr:potentialImpactText>The primary aim of this proposal is to benefit patients with neurological deficits, the healthcare/biotech industry, the NHS and the tax-payer by enhancing neuronal differentiation and maturation in vitro along with controlling neuronal subtype choice to significantly enhance the utility of patient-specific disease modeling and generation of neurons for cell replacement therapies. In detail:

Who will benefit?
Patients, health-care providers and biomedical science and allied industries will benefit.

This proposal is centred on developing improved disease models for neurological disorders and neurodegenerative conditions that are widely prevalent and are rising fast in our aging community. In addition this project will potentially enhance methods undertaken to generate neurons in vitro for cell replacement therapies. Our work in basic biology has uncovered a way to promote neuronal differentiation and maturation from human cells in vitro more effectively than current protocols, and may simultaneously influence neuronal subtype choice, benefiting all those groups with an interest in improving and enhancing these processes.

How will they benefit?
This work, grounded in the basic developmental biology of proneural protein regulation, indicates a way to enhance neuronal differentiation of human ES cells and human fibroblasts in vitro. Moreover, it points towards a regulate-able way to manipulate the type of neuron generated in vitro. Both these advances will lead to better &amp;quot;disease-in-a-dish&amp;quot; models for neurological deficits. These are likely to be suitable both for detailed phenotypic analysis of neurons and also to test novel therapeutics for efficacy before use in animal models and human trials so benefitting patients, health-care providers and biomedical science and allied industries. Moreover, the scientific community will benefit from an enhanced understanding of the basic biology of neuronal differentiation, maturation and subtype choice, as well as development of better methods for neuron production. These benefits will be realised within the life of this grant or shortly after.

Generation of more mature human neurons of specific subtypes in vitro is a prerequisite step for producing neurons to repair or replace the underlying neurological deficits of a number of devastating and prevalent conditions, for instance nigral dopaminergic neurons in Parkinsons disease, cortical neurons for stroke and motor neurons for spinal cord injury. For these reasons, patients with neurological deficits will benefit from better patient-specific disease modeling and potentially enhanced cell based therapies, while health-care providers and allied industries will benefit by developing these therapies. While the advance at producing neurons should be very rapid, within the life-time of this grant, it would take at least 5 years to take these advances further into patients, and rodent xenograft trials would certainly be the next step (already planed with Prof Roger Barker).

Findings about post-translational regulation of proneural proteins is likely to be applicable to proneural proteins active in other tissues such as Ngn3 that controls differentiation of pancreatic beta cells. Implications of this work may therefore extend beyond neurosciences. We aim to maximise this impact by running parallel programs in the lab on complimentary aspects of proneural control in the nervous system and pancreas (an area where we have an MRC Research grant already funded).</gtr:potentialImpactText><gtr:fund><gtr:end>2018-01-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-01-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>647732</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Gene Center Munich</gtr:department><gtr:description>phosphomutant proneurals for reprogramming</gtr:description><gtr:id>9859EC2B-BBC9-4797-A277-62EFFF3CD28A</gtr:id><gtr:impact>Reagents have been exchanged, awaiting outcome of experiments</gtr:impact><gtr:outcomeId>58b97c95e04776.25690399-1</gtr:outcomeId><gtr:partnerContribution>Testing mutant proneural genes for enhanced reprogramming activity</gtr:partnerContribution><gtr:piContribution>providing mutant proneural gene constructs to aid in vivo neural reprogramming</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genome-wide transcriptome analysis</gtr:description><gtr:id>6C6B35A9-800F-4DA1-81B3-F4C3789618E6</gtr:id><gtr:impact>Data-set of genome-wide transcription factor binding sites and mRNA changes.</gtr:impact><gtr:outcomeId>56c45c769d12f8.14019114-1</gtr:outcomeId><gtr:partnerContribution>They undertook the sequencing for genome-wide analysis and provided bioinformatics support.</gtr:partnerContribution><gtr:piContribution>We provided samples to allow genome-wide RNAseq and ChiPseq analysis of transcription factor binding, producing a large data-set that will become publicly available.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Geography</gtr:department><gtr:description>modulation of E protein activity in vivo</gtr:description><gtr:id>8A094564-1B56-4F6B-9A7D-CD02FB956A6C</gtr:id><gtr:impact>Targeted mouse ES cells have been generated en route to production of a transgenic animal.</gtr:impact><gtr:outcomeId>58b95f41e734e1.91186990-1</gtr:outcomeId><gtr:partnerContribution>They are generating a transgenic ES cell and ultimately a mouse line to test the effect of expression of mutated E proteins.</gtr:partnerContribution><gtr:piContribution>We provided modified E protein plasmids along with technical and intellectual input into this project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit to Calre College</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6A9D0FE3-6F94-48E9-85B8-2C47C931A177</gtr:id><gtr:impact>Presentation of our research to year 11 school children from a target economically disadvantaged area (Tower Hamlets) to encourage them to aim higher and think about applying to Cambridge by showcasing my research.</gtr:impact><gtr:outcomeId>58b95a49bfce09.15141296</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Outreach talk in Clare College</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4C9C4103-C837-426F-839D-897A8DE90055</gtr:id><gtr:impact>30 year 11 pupils came to Clare College to demystify the Cambridge application process and part of this was my giving a talk about my own research interests, pitched at a level appropriate for Year 11s, to show them what real research is like.</gtr:impact><gtr:outcomeId>56c45eae79bdd0.69246565</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stem cells school visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C0B91CBF-5157-4F4F-AC42-42E3BDE17DB6</gtr:id><gtr:impact>24 pupils attended an interactive session on how stem cells contribute to your body. this involved discussion and model-making.</gtr:impact><gtr:outcomeId>58b959adbd1358.81648784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>172000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>The Neuroblastoma Society</gtr:fundingOrg><gtr:id>7E1DB496-4852-4733-8E9A-972478D9D55D</gtr:id><gtr:outcomeId>56bdfad1eb7f40.76139646</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>List of proteins identified to associate with either wild-type or dephosphorylated Ascl1 in neuroblastoma cells as revealed by proteome-wide Mass Spectrometry.</gtr:description><gtr:id>EF58F22B-A463-4833-9F56-5D3377BE8F6D</gtr:id><gtr:impact>reveals mechanisms for activity of Ascl1 that have formed the basis for a further grant application.</gtr:impact><gtr:outcomeId>58b9610aea4791.75961534</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RIME Ascl1 associated proteins</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Genome-wide dataset of Ascl1 binding sites and transcriptional outputs when Ascl1 is over expressed.</gtr:description><gtr:id>E94E1E95-E283-4585-ACA3-EEFB0A79406B</gtr:id><gtr:impact>Informs further experiments to define mechanisms of transcriptional regulation by Ascl1.</gtr:impact><gtr:outcomeId>56c460af4627b3.74007425</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ChIPseq/RNAseq of Ascl1 targets</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Ascl1 where lysines are mutated to prevent degradation by ubiquitination</gtr:description><gtr:id>D08219B0-A207-43B6-88C2-C3440130B677</gtr:id><gtr:impact>Used to determine mode of degradation of the key stem/progenitor regulator Ascl1.</gtr:impact><gtr:outcomeId>58b961bf88ec08.50947637</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Ascl1 lysine mutant</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CD40DDD5-5FCD-49A8-BED2-CBC1238099D9</gtr:id><gtr:title>Cell cycle regulation of proliferation versus differentiation in the central nervous system.</gtr:title><gtr:parentPublicationTitle>Cell and tissue research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e3bd53c935f643aab5b8c97e7f6e3f0"><gtr:id>3e3bd53c935f643aab5b8c97e7f6e3f0</gtr:id><gtr:otherNames>Hardwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-766X</gtr:issn><gtr:outcomeId>doi_55f9849846a58f77</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98BAE979-5D30-4EB7-B31C-A6F3235ECC88</gtr:id><gtr:title>Multi-site phosphorylation regulates NeuroD4 activity during primary neurogenesis: a conserved mechanism amongst proneural proteins.</gtr:title><gtr:parentPublicationTitle>Neural development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e3bd53c935f643aab5b8c97e7f6e3f0"><gtr:id>3e3bd53c935f643aab5b8c97e7f6e3f0</gtr:id><gtr:otherNames>Hardwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1749-8104</gtr:issn><gtr:outcomeId>5675e6c22cd30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE73A7CE-77AF-42A7-87FB-78CFCF27D469</gtr:id><gtr:title>Emergence of neuronal diversity from patterning of telencephalic progenitors.</gtr:title><gtr:parentPublicationTitle>Wiley interdisciplinary reviews. Developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f26d54a3ced3310bae19e29b38dd4bd"><gtr:id>2f26d54a3ced3310bae19e29b38dd4bd</gtr:id><gtr:otherNames>Azzarelli R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-7684</gtr:issn><gtr:outcomeId>5675defb240e0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>392C15FE-AC55-4B80-93F0-A7D8AD965B33</gtr:id><gtr:title>MyoD phosphorylation on multiple C terminal sites regulates myogenic conversion activity.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e3bd53c935f643aab5b8c97e7f6e3f0"><gtr:id>3e3bd53c935f643aab5b8c97e7f6e3f0</gtr:id><gtr:otherNames>Hardwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>585d337ee5c086.03459952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E085F77-2A31-4B6B-93A8-7F6634FD60FB</gtr:id><gtr:title>Ubiquitin-mediated proteolysis in Xenopus extract.</gtr:title><gtr:parentPublicationTitle>The International journal of developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430fcb4eb3500fa5cf1c801d36bd7bf0"><gtr:id>430fcb4eb3500fa5cf1c801d36bd7bf0</gtr:id><gtr:otherNames>McDowell GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0214-6282</gtr:issn><gtr:outcomeId>5a361e2f581088.20946991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6B9CB08-B8E1-4A30-A790-13ABC32CFE81</gtr:id><gtr:title>Multi-site Neurogenin3 Phosphorylation Controls Pancreatic Endocrine Differentiation.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f26d54a3ced3310bae19e29b38dd4bd"><gtr:id>2f26d54a3ced3310bae19e29b38dd4bd</gtr:id><gtr:otherNames>Azzarelli R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>5a31d8680ff606.61517445</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L021129/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>